Abstract
Introduction: Fu-Fang-Jin-Qian-Cao is a Chinese herbal preparation used to treat urinary calculi. Fu-Fang-Jin-Qian-Cao can protect renal tubular epithelial cells from calcium oxalateinduced renal injury by inhibiting ROS-mediated autopathy. The mechanism still needs further exploration. Metabonomics is a new subject; the combination of metabolomics and network pharmacology can find pathways for drugs to act on targets more efficiently.
Methods: Comprehensive metabolomics and network pharmacology to study the mechanism of Fu-Fang-Jin-Qian-Cao inhibiting autophagy in calcium oxalate-induced renal injury. Based on UHPLC-Q-TOF-MS, combined with biochemical analysis, a mice model of Calcium oxalateinduced renal injury was established to study the therapeutic effect of Fu-Fang-Jin-Qian-Cao. Based on the network pharmacology, the target signaling pathway and the protective effect of Fu- Fang-Jin-Qian-Cao on Calcium oxalate-induced renal injury by inhibiting autophagy were explored. Autophagy-related proteins LC3-II, BECN1, ATG5, and ATG7 were studied by immunohistochemistry.
Results: Combining network pharmacology and metabolomics, 50 differential metabolites and 2482 targets related to these metabolites were found. Subsequently, the targets enriched in PI3KAkt, MAPK and Ras signaling pathways. LC3-II, BECN1, ATG5 and ATG7 were up-regulated in Calcium oxalate-induced renal injury. All of them could be reversed after the Fu-Fang-Jin-Qian- Cao treatment.
Conclusions: Fu-Fang-Jin-Qian-Cao can reverse ROS-induced activation of the MAPK signaling pathway and inhibition of the PI3K-Akt signaling pathway, thereby reducing autophagy damage of renal tubular epithelial cells in Calcium oxalate-induced renal injury.
Graphical Abstract
[http://dx.doi.org/10.1038/s41581-020-0320-7] [PMID: 32753740]
[http://dx.doi.org/10.1177/1535370213493069] [PMID: 23856898]
[http://dx.doi.org/10.1007/s00467-009-1116-y] [PMID: 19198886]
[http://dx.doi.org/10.1016/j.juro.2012.05.078] [PMID: 23022011]
[http://dx.doi.org/10.3978/j.issn.2223-4683.2014.06.04] [PMID: 25383321]
[http://dx.doi.org/10.1089/cbr.2016.2057] [PMID: 27754749]
[http://dx.doi.org/10.1016/j.molcel.2010.09.023] [PMID: 20965422]
[http://dx.doi.org/10.1016/j.jmb.2017.01.002] [PMID: 28077293]
[http://dx.doi.org/10.1161/CIRCRESAHA.108.175448] [PMID: 18703786]
[http://dx.doi.org/10.3892/ijmm.2012.911] [PMID: 22322529]
[http://dx.doi.org/10.1152/ajprenal.00590.2007] [PMID: 18256309]
[http://dx.doi.org/10.3389/fphar.2018.00620] [PMID: 29950996]
[http://dx.doi.org/10.1007/s00240-017-0985-y] [PMID: 28567512]
[http://dx.doi.org/10.1080/13880209.2020.1844241] [PMID: 33191819]
[http://dx.doi.org/10.1042/BSR20181833] [PMID: 30737304]
[http://dx.doi.org/10.1016/j.jchromb.2021.122525] [PMID: 33454441]
[http://dx.doi.org/10.1093/nar/gky310] [PMID: 29762782]
[http://dx.doi.org/10.1093/nar/gkv1277] [PMID: 26590256]
[http://dx.doi.org/10.1038/nprot.2007.324] [PMID: 17947979]
[http://dx.doi.org/10.1016/j.cell.2012.03.017] [PMID: 22500797]
[http://dx.doi.org/10.1080/15548627.2016.1203483] [PMID: 27459239]
[http://dx.doi.org/10.1101/gad.2016311] [PMID: 21317241]
[http://dx.doi.org/10.1371/journal.pone.0030312] [PMID: 22276178]
[http://dx.doi.org/10.4161/auto.6309] [PMID: 18497570]
[http://dx.doi.org/10.1007/s11255-009-9534-0] [PMID: 19241135]
[http://dx.doi.org/10.1016/j.ejphar.2007.09.044] [PMID: 18001705]
[http://dx.doi.org/10.1016/j.bbrc.2016.11.088] [PMID: 28212726]
[http://dx.doi.org/10.3389/fpls.2015.00769] [PMID: 26442079]
[http://dx.doi.org/10.3892/ijo.2013.1959] [PMID: 23708970]
[http://dx.doi.org/10.1038/cddis.2013.165] [PMID: 23703386]
[http://dx.doi.org/10.1248/bpb.34.47] [PMID: 21212516]
[http://dx.doi.org/10.1152/ajpheart.01051.2008] [PMID: 19098111]
[http://dx.doi.org/10.18632/oncotarget.1775] [PMID: 24583697]
[PMID: 16013027]
[http://dx.doi.org/10.1159/000070236] [PMID: 12759573]